Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C
NCT ID: NCT00309530
Last Updated: 2006-04-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
598 participants
INTERVENTIONAL
1990-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5-fluorouracil, levamisol, interferon
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: less than 80 years
* WHO Performace Status \> 2
* Adequate bone marrow reserve
* Informed consent
Exclusion Criteria
* R1, R2, carcinosis peritonei
* Start of chemo- or chemo-immunotherapy \> 42 days postop; other adjuvant radiotherapy, chemotherapy or immunotherapy
* Serious concomitant disease, in particular chronically inflammatory large intestine, cardiopathic disease, malignant second carcinoma
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Austrian Breast & Colorectal Cancer Study Group
NETWORK
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raimund Jakesz, MD
Role: PRINCIPAL_INVESTIGATOR
Austrian Breast & Colorectal Cancer Study Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Guessing
Güssing, Burgenland, Austria
Hospital Oberpullendorf
Oberpullendorf, Burgenland, Austria
Hospital BHB St. Veit/Glan, Surgery
Saint Veit A. D. Glan, Carinthia, Austria
State Hospital Wolfsberg
Wolfsberg, Carinthia, Austria
Paracelsus Medical University Salzburg - Oncology
Salzburg, Salzburg, Austria
Medical University of Graz, Oncology
Graz, Styria, Austria
State Hospital Leoben, Surgery
Leoben, Styria, Austria
Hospital St. Vinzenz
Zams, Tyrol, Austria
State Hospital Kirchdorf
Kirchdorf, Upper Austria, Austria
General Hospital Linz
Linz, Upper Austria, Austria
Hospital BHB Linz
Linz, Upper Austria, Austria
State Hospital Voecklabruck, Internal Medicine
Vöcklabruck, Upper Austria, Austria
Hospital Kreuzschwestern Wels
Wels, Upper Austria, Austria
Medical University Vienna, General Hospital
Vienna, Vienna, Austria
Wilheminenspital, Internal Medicin I
Vienna, Vienna, Austria
State Hospital Feldkirch
Feldkirch, Vorarlberg, Austria
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABCSG 90
Identifier Type: -
Identifier Source: org_study_id